Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...

One particular S&P 500 biotech continues to stink out our writer's Stocks and Shares ISA. Is it time he chucked in the towel? The post This S&P 500 stock could surge 55% in just 12 months, according ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

Growth in the Lipid Nanoparticles (LNPs) market is driven by increasing demand for mRNA-based therapeutics and advances in ...

The need to keep Canada’s health data secure and independent is urgent, especially in today’s changing political climate, but ...

The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...